This activity is supported by an independent education grant from Lilly. This online education program has been designed for healthcare professionals globally, excluding the UK.

Target Audience
This activity is intended for rheumatologists who care for patients with psoriatic arthritis (PsA).

Faculty

Prof. Peter Korsten

Prof. Peter Korsten is Chief of the Department of Rheumatology and Clinical Immunology at St. Josef-Stift Sendenhorst, Germany. His research focuses on outcomes in rheumatology, with particular expertise in rare systemic autoimmune diseases, including sarcoidosis, systemic lupus erythematosus, myositis, and systemic sclerosis, as well as musculoskeletal ultrasound.

Disclosures

Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.

Dr. Peter Korsten, faculty for this educational activity, has the following relevant financial relationships:
Speaker fees and travel expense support: AbbVie, Alexien, Alfasigma, Apheresis Research Institute, AstraZeneca, Boehringer-Ingelheim, Celltrion, CSL Vifor, GlaxoSmithKline, medac, Novartis, Pfizer, Sanofi.
Principal investigator in clinical trials: Alexien, Alfasigma, Argenx, AstraZeneca, CSL Vifor, Novartis

The MedAll staff, program planners, and reviewers have no relevant financial relationships with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Education

Partners designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.25 hour(s). To successfully complete this activity and receive CE credit, learners must follow these steps during the period from August 31st 2026 through to May 29th 2027.

Review the objectives and disclosures
Study the educational content
Successfully complete activity post-test(s)
Complete the activity evaluation

This continuing education activity is active starting August 31st 2026, and will expire on June 14th 2027.

Estimated time to complete this activity: 15 minutes.

Abbreviations: ACR, American College of Rheumatology; BMI, body mass index; CRP, C-reactive protein; IL, interleukin; MDA, minimal disease activity; PsA, psoriatic arthritis; TNF, tumor necrosis factor

References

• Versini M, et al. Autoimmun Rev. 2014;13(9):981-1000;
• Haberman RH, et al. Nat Rev Rheumatol. 2026;22(3):151-164;
• Tilg H, Moschen AR. Nat Rev Immunol. 2006;6(10):772-783;
• Kumthekar A, Ogdie A. Rheumatol Ther. 2020;7(3):447-456.
• Di Minno MND, et al. Ann Rheum Dis. 2014;73(6):1157-1162.
• Merola JF, et al. Arthritis Rheumatol. 2026 Mar 28. doi: 10.1002/art.70134
• Gorgojo-Martínez JJ, et al. J Clin Med. 2022;12(1):145
• Mehta P, et al. Rheumatology (Oxford). 2026;65(7):keag303
• Gossec L, et al. Ann Rheum Dis. 2024;83(6):706–719;
• Coates LC, et al. Arthritis Rheumatol. 2016;68(5):1060–1071;
• Gossec L, et al. Ann Rheum Dis. 2024;83(6):706-719
• Rubino F, et al. Nat Med. 2020;26(4):485-497;
• Puhl RM, Heuer CA. Obesity (Silver Spring). 2009;17(5):941-964
• Zangi HA, et al. Ann Rheum Dis. 2015;74(6):954-962.